Amuvatinib, a multitargeted RTK inhibitor that targets AXL, KIT, and PDGFRα [140], was shown to disrupt DNA damage repair through the inhibition of Rad51 [185], to suppress AXL expression [186] and to resensitize cells to radio- and chemotherapies in GIST, lung cancer and glioblastoma cells [118, 140, 185–187]. This evidence concerns the gene AXL and lung cancer.